Visceral Fat, Weight Loss
Conditions
Keywords
High visceral fat, Low calorie diet, Mild weight loss, Metabolomics, Metabolites, Acylcarnitines
Brief summary
To determine whether low calorie diet (LCD)-induced weight reduction caused changes in plasma metabolites and metabolic traits from baseline.
Detailed description
Over a 12-week clinical intervention period, a randomized, controlled study was carried out; overweight subjects consumed a LCD (approximately 300kcal/d deficit, n=47) or a weight-maintenance diet (control, n=50) were included for analyzing plasma samples and metabolites using an ultra-performance liquid chromatography and mass spectrometry (UPLC-LTQ/Orbitrap MS).
Interventions
BEHAVIORALControl group
Recommend to consume usual diet during 12-week study period
BEHAVIORALLCD group
Recommended to reduce calorie intake (a 300 kcal/day); educated to take out 1/3 of a bowl of rice from per meal a day for an easier application of 100kcal deficits, thereby reducing a 300kcal/3 meal/day
Sponsors
Yonsei University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
20 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
* Able to give informed consent * 20-65 years old * Males and females * Overweight (25.0 kg/m²≤ Body mass index \<30 kg/m²) * Nondiabetic (Fasting glucose \<126 mg/dL)
Exclusion criteria
* Unstable body weight (body weight change \>1 kg within 3 months before screening) * Consumption of medication that affects body weight or energy expenditure * Pregnancy or breast-feeding * Hypertension, type 2 diabetes, cardiovascular disease, cerebrovascular disease, or thyroid disease * Liver disease, kidney disease, or gastrointestinal disease * Acute or chronic infections * Any acute or chronic disease requiring treatment
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Visceral fat area at L4 (CT) | At baseline |
| Change in visceral fat area at L4 from baseline | At baseline and 12-week follow-up |
| Putatively identified plasma metabolites (Normalized peak intensities) | At baseline |
| Changes in putatively identified plasma metabolites (Normalized peak intensities) from baseline | At baseline and 12-week follow-up |
Countries
South Korea
Outcome results
None listed